Vir Biotechnology, Inc., a clinical-stage immunology company headquartered in San Francisco, United States, has recently filed a Form 4 with the Securities and Exchange Commission (SEC) to report changes in the beneficial ownership of its common stock. The filing, which provides transparency into the company’s internal shareholding adjustments, lists More Robert J, a director of Vir Biotechnology, as the reporting owner.
The transactions detailed in the filing occurred on August 11, 2026, and involved two key actions. Initially, More Robert J exchanged 8,000 shares of Vir Biotechnology’s common stock for no consideration. Subsequently, these 8,000 shares were transferred to Alta Partners NextGen Fund I, L.P. (APNG 1) in connection with the vesting of restricted stock unit awards. It is important to note that these transactions did not involve any monetary consideration, and the net change in ownership maintained the director’s overall stake in the company.
The filing confirms that More Robert J remains a direct and indirect owner of the transferred shares, with the transfer to APNG 1 occurring specifically for vesting purposes. This disclosure ensures that stakeholders are informed about the director’s shareholding adjustments, reinforcing the company’s commitment to transparency.
Vir Biotechnology, Inc. operates within the Health Care sector and is listed on the Nasdaq stock exchange. As of August 13, 2026, the company’s close price was $9.24, with a 52-week high of $11.66 recorded on April 19, 2026, and a 52-week low of $4.25 on August 20, 2025. The company’s market capitalization stands at $1.52 billion USD. Despite its focus on developing and commercializing therapeutics and medicines for viral and bacterial diseases, the company currently reports a price-earnings ratio of -5.31, reflecting its status as a clinical-stage entity.
Vir Biotechnology serves customers primarily in the state of California, continuing its mission to advance treatments and preventions for infectious diseases through innovative immunological research and development.
